ecteinascidin 743 has been researched along with Carcinoma, Ductal, Breast in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alfaro, V; Blum, JL; Byrski, T; Campone, M; Cullell-Young, M; Delaloge, S; Ghouadni, A; Gonçalves, A; Kahatt, C; Lardelli, P; Lubinski, J; Nieto, A | 1 |
| Bayever, E; Del Prete, SA; Goldstein, LJ; Gurtler, J; Michiels, B; Semiglazov, VF; Tjulandin, S | 1 |
2 trial(s) available for ecteinascidin 743 and Carcinoma, Ductal, Breast
| Article | Year |
|---|---|
Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial.
Topics: Adult; Antineoplastic Agents, Alkylating; Breast Neoplasms; Carcinoma, Ductal, Breast; Dioxoles; Female; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Heterozygote; Humans; Middle Aged; Response Evaluation Criteria in Solid Tumors; Tetrahydroisoquinolines; Trabectedin | 2017 |
Trabectedin as a single-agent treatment of advanced breast cancer after anthracycline and taxane treatment: a multicenter, randomized, phase II study comparing 2 administration regimens.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Dioxoles; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate; Taxoids; Tetrahydroisoquinolines; Trabectedin; Young Adult | 2014 |